Literature DB >> 30338828

Over-expression of mir-124 inhibits MMP-9 expression and decreases invasion of renal cell carcinoma cells.

P Wang1, L-D Zhang, M-C Sun, W-D Gu, H-Z Geng.   

Abstract

OBJECTIVE: JAK-STAT3 signaling pathway is related to tumor invasion and metastasis that can regulate matrix metalloproteinase-9 (MMP-9) expression. MicroRNA-124 (MiR-124) was found downregulated in renal cell carcinoma. Bioinformatics analysis revealed the complementary binding site between miR-124 and 3'-UTR of signal transducers and activators of transcription 3 (STAT3). This study investigated the role of miR-124 in regulating Janus kinase (JAK)-STAT3 activity, MMP-9 expression, and renal cell carcinoma invasion.
MATERIALS AND METHODS: Luciferase assay was used to test the targeting regulatory effect of miR-124 on STAT3. MiR-124, STAT3, phosphorylated STAT3 (p-STAT3), and MMP-9 expressions were compared in HK-2, 769-P, and OS-RC-2 cells. Transwell assay was applied to evaluate cell invasion. OS-RC-2 cells were divided into control, miR-NC, miR-124 mimic, STAT3 inhibition, and miR-124 mimic+Stattic groups.
RESULTS: MiR-124 targeted inhibited STAT3 expression. OS-RC-2 cells exhibited the strongest invasive ability, followed by 769-P and HK-2 cells. STAT3, p-STAT3, and MMP-9 expressions were highest in OS-RC-2 cells, followed by 769-P and HK-2 cells. MiR-124 demonstrated the opposite expression trend. MiR-124 mimic and/or Stattic treatment attenuated cell invasion through reducing STAT3, p-STAT3, and MMP-9 levels.
CONCLUSIONS: MiR-124 down-regulation was associated with renal cancer cell OS-RC-2 invasion enhancement. Over-expression of miR-124 attenuated OS-RC-2 cell invasion by down-regulating STAT3 and MMP-9.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30338828     DOI: 10.26355/eurrev_201810_16041

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  9 in total

Review 1.  The Impact of Matrix Metalloproteinase-9 on the Sequential Steps of the Metastatic Process.

Authors:  Giovanni Barillari
Journal:  Int J Mol Sci       Date:  2020-06-25       Impact factor: 5.923

2.  MiR-124-3p.1 Sensitizes Ovarian Cancer Cells to Mitochondrial Apoptosis Induced by Carboplatin.

Authors:  Xiaohong Deng; Yi Chen; Zhao Liu; Jingning Xu
Journal:  Onco Targets Ther       Date:  2020-06-10       Impact factor: 4.147

3.  ISG20 serves as a potential biomarker and drives tumor progression in clear cell renal cell carcinoma.

Authors:  Tianbo Xu; Hailong Ruan; Su Gao; Jingchong Liu; Yuenan Liu; Zhengshuai Song; Qi Cao; Keshan Wang; Lin Bao; Di Liu; Junwei Tong; Jian Shi; Huageng Liang; Hongmei Yang; Ke Chen; Xiaoping Zhang
Journal:  Aging (Albany NY)       Date:  2020-01-30       Impact factor: 5.682

4.  The COX-2-derived PGE2 autocrine contributes to bradykinin-induced matrix metalloproteinase-9 expression and astrocytic migration via STAT3 signaling.

Authors:  Tsong-Hai Lee; Pei-Shan Liu; Ming-Ming Tsai; Jiun-Liang Chen; Su-Jane Wang; Hsi-Lung Hsieh
Journal:  Cell Commun Signal       Date:  2020-11-23       Impact factor: 5.712

Review 5.  Neuroimmune crosstalk and its impact on cancer therapy and research.

Authors:  Iman Sharawy
Journal:  Discov Oncol       Date:  2022-08-23

6.  MiR-124 Negatively Regulated PARP1 to Alleviate Renal Ischemia-reperfusion Injury by Inhibiting TNFα/RIP1/RIP3 Pathway.

Authors:  Jing Ke; Fan Zhao; Yanwen Luo; Fangjing Deng; Xiongfei Wu
Journal:  Int J Biol Sci       Date:  2021-05-13       Impact factor: 6.580

Review 7.  MicroRNAs: emerging driver of cancer perineural invasion.

Authors:  Mei Zhang; Hong-Chun Xian; Li Dai; Ya-Ling Tang; Xin-Hua Liang
Journal:  Cell Biosci       Date:  2021-06-29       Impact factor: 7.133

8.  MiR-124 sensitizes cisplatin-induced cytotoxicity against CD133+ hepatocellular carcinoma cells by targeting SIRT1/ROS/JNK pathway.

Authors:  Yunxiuxiu Xu; Yu Lai; Hanqin Weng; Lanping Tan; Yanshan Li; Guangcheng Chen; Xingxi Luo; Yibiao Ye
Journal:  Aging (Albany NY)       Date:  2019-05-05       Impact factor: 5.682

Review 9.  MicroRNA-124: An emerging therapeutic target in cancer.

Authors:  Xinqi Jia; Xu Wang; Xiaorong Guo; Jingjing Ji; Ge Lou; Junjie Zhao; Wenjia Zhou; Mian Guo; Maomao Zhang; Chao Li; Sheng Tai; Shan Yu
Journal:  Cancer Med       Date:  2019-08-06       Impact factor: 4.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.